|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the effects of IFN-λ on autophagy, a cellular process closely related to hepatitis C virus (HCV) infection in human hepatoma Huh7 cells.
|
28131804 |
2017 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, emerging data show that IFN-induced SVR is associated with lower incidences of hepatocellular carcinoma compared with DAAs.
|
28992878 |
2017 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A systematic review was conducted to identify trials about curative treatment combined with or without adjuvant therapies (interferon, IFN; or transarterial chemoembolization, TACE) for HCC.
|
29163828 |
2017 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There has been some debate if IFN-free therapy with direct-acting antivirals alters the risk for HCC.
|
29205405 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study conducted a meta-analysis to evaluate the effects of adjuvant Peg-IFN-based therapy on the survival outcomes in patients with hepatitis-related HCC after the curative treatment.
|
29995763 |
2018 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In patients with previous HCC treated with curative therapies, HCC recurrence occurred in two (25%) out of eight patients treated with IFN-based regimens and four (21%) out of 19 treated with DAA-IFN-free regimens (P = 1.0).
|
29596108 |
2018 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression.
|
29377616 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study aimed to investigate the clinical efficacy of single agent S-1 and S-1/IFN-α for HCC patients with extrahepatic metastases in a randomized, open-label, multicenter trial.
|
29377364 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, after 9 months of treatment with subcutaneous injections of PEG-IFNα 2a once per week, the metastatic lung foci gradually shrunk until disappearance and the HCC lesion stabilized without progression.
|
30127887 |
2018 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, we failed to uncover any significant association between other polymorphisms in genes of IL-12 signaling pathway and HCC risk, including <i>IL18</i>-rs1946518 and -rs187238, <i>IFN-γ</i>-rs2430561, <i>IL12A</i>-rs568408, <i>IL12B</i>-rs3212227 and <i>STAT4</i>-rs7574865.
|
30310516 |
2018 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PD-L1 positive HCC was observed in 6 cases of the IFN group and 4 cases of the DAA group.
|
31423211 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared with IFN-only regimen, no significant increase in HCC risk was found for use of DAA-only (HR, 1.53; 95% CI, 0.73-3.23), DAA + IFN (HR, 1.02; 95% CI, 0.51-2.06), or any-DAA (HR, 1.04; 95% CI, 0.65-1.65).
|
31451519 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We further found that RIP3 knockdown results in an increase of MDSCs and a decrease of interferon gamma-positive (IFN-γ<sup>+</sup> ) cluster of differentiation 8-positive (CD8<sup>+</sup> ) tumor-infiltrating lymphocytes (IFN-γ<sup>+</sup> CD8<sup>+</sup> T cells) in hepatoma tissues, thus promoting immune escape and HCC growth in immunocompetent mice.
|
31021443 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
With CTLA-4 Nb16 stimulation, dendritic cell/hepatocellular carcinoma fusion cells (DC/HepG2-FCs) enhanced autologous CD8<sup>+</sup> T cell proliferation and production of IFN-<i>γ</i><i>in vitro</i>, thereby leading to enhanced killing of tumor cells.
|
31847937 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treating with anti-HN neutralizing mAb induced significant decline in the cytotoxicity of IFN R<sup>-/-</sup> NK cells toward Hepa1-6 cell line (P < 0.05).
|
31120191 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Only APRI was associated with HCC recurrence; and post-IFN AFP and HCC recurrence were predictive of subsequent mortality independently.
|
30527565 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, our study suggests that HBV precore protein, specifically the p22 form, impedes JAK-STAT signaling to help the virus evade the host innate immune response and, thus, causes resistance to IFN therapy.<b>IMPORTANCE</b> Chronic hepatitis B virus (HBV) infection continues to be a major global health concern, and patients who fail to mount an efficient immune response to clear the virus will develop a life-long chronic infection that can progress to chronic active hepatitis, cirrhosis, and primary hepatocellular carcinoma.
|
31019054 |
2019 |